ARCHIVES

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

This article is from The Cancer Letter archive.

Vol. 30 No. 46 | December 10, 2004

Download PDF Visit The Full Archive

Related Articles

The March: Cancer Centers To Plan Events In Conjunction With Sept. 26 March

April 10, 1998

In Brief: Weicker Joins Tobacco Company Board; Hatfield To Leave Senate Next Year

December 8, 1995

Amgen’s Kepivance Approved For Severe Oral Mucositis

January 28, 2005

Letter to the Editors: AACR Defends Policy Paper And Work Of Barker, Sigal.

June 27, 2003

Masons Give $65 Million to Univ. of Minnesota Cancer Center.

April 25, 2008

European regulators plan more rigorous rules for accelerated approval in cancer.

November 11, 2005